BioDelivery Sciences International Inc. (NASDAQ:BDSI) shares rose 0.8% during trading on Wednesday . The stock traded as high as $2.47 and last traded at $2.45, with a volume of 233,232 shares trading hands. The stock had previously closed at $2.43.

BDSI has been the subject of several recent research reports. Piper Jaffray Cos. reissued a “sell” rating and set a $4.00 price target on shares of BioDelivery Sciences International in a research report on Wednesday, August 10th. Janney Montgomery Scott reissued a “hold” rating and set a $4.00 price target on shares of BioDelivery Sciences International in a research report on Tuesday, July 12th. Cantor Fitzgerald reissued a “hold” rating on shares of BioDelivery Sciences International in a research report on Wednesday, August 10th. Zacks Investment Research cut BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 12th. Finally, FBR & Co reaffirmed a “buy” rating on shares of BioDelivery Sciences International in a research report on Thursday, May 12th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $8.25.

The firm has a 50-day moving average price of $2.54 and a 200 day moving average price of $2.86. The stock’s market cap is $131.42 million.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.31) EPS for the quarter, meeting the consensus estimate of ($0.31). The firm earned $5 million during the quarter, compared to analysts’ expectations of $3.35 million. BioDelivery Sciences International’s revenue for the quarter was up 194.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.37) EPS. Equities research analysts expect that BioDelivery Sciences International Inc. will post ($1.14) EPS for the current year.

In related news, Director William B. Stone sold 16,000 shares of the company’s stock in a transaction that occurred on Thursday, August 11th. The stock was sold at an average price of $2.57, for a total value of $41,120.00. Following the transaction, the director now owns 122,675 shares in the company, valued at $315,274.75. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.